Imalia

  • Biotech or pharma, therapeutic R&D

Imalia is a Swiss biotech company, developing a breakthrough therapy for sickle cell disease. Our lead asset, IMA001, is a first-in-class small molecule that targets red blood cell metabolism through a novel dual mechanism of action, addressing the root cause of this life-threatening condition.

Address

Switzerland

Website

https://imalia.ch/

Contact Exhibitor


Loading
View all Partnering Companies

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS